Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MT-3724 1st-Generation Forced Internalization Novel MOA CD20 B-Cell Malignancies CD20 Internalization Novel MOA

79

MT-4019 2nd-Generation
De-immunized CD38 Multiple Myeloma Active on CD38 low, CD55/CD59 high tumor cells

42

MT-5111 2nd-Generation
De-immunized HER2 Breast Cancer Novel epitope/combinable with Kadcyla Novel MoA
Active in Kadcyla-refractory cells

37

MT-5050 PD-L1+ tumors PD-L1 Melanoma Novel MoA Antigen seeding

25

MT-6868 1st-Generation CD45 SCT Novel MOA